Ascendis Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	13,924	13,216	8,238	7,123	6,832	7,369
Market Cap Growth	-	60.42%	15.65%	4.26%	-7.28%	-17.80%
Enterprise Value	14,211	12,945	8,036	6,928	6,562	6,705
Last Close Price	224.11	213.24	137.67	125.95	122.14	134.54
PS Ratio	13.86	15.64	21.77	24.16	124.47	833.13
PB Ratio	26.22	-69.18	-74.90	-44.23	24.19	7.33
P/TBV Ratio	28.75	-79.37	-75.40	-48.66	26.01	8.34
P/FCF Ratio	263.70	209.00	-	-	-	-
P/OCF Ratio	198.40	209.00	-	-	-	-
EV/Sales Ratio	14.24	15.32	21.24	23.50	119.53	758.03
EV/FCF Ratio	270.82	204.71	-	-	-	-
Debt / Equity Ratio	0.79	-2.37	-3.45	-1.53	1.83	0.11
Debt / EBITDA Ratio	87.54	-	-	-	-	-
Debt / FCF Ratio	14.82	16.18	-	-	-	-
Net Debt / Equity Ratio	0.66	-1.57	-2.81	-1.68	-0.86	-0.65
Net Debt / EBITDA Ratio	31.62	-2.16	-1.14	-0.56	0.42	1.32
Net Debt / FCF Ratio	5.35	4.75	-0.97	-0.52	0.46	1.31
Asset Turnover	0.52	0.58	0.36	0.28	0.05	0.01
Inventory Turnover	0.10	-0.32	-0.18	0.26	-0.12	-0.09
Quick Ratio	0.68	0.72	0.81	0.62	4.44	7.03
Current Ratio	1.00	1.04	1.17	0.95	5.39	8.03
Return on Equity (ROE)	305.05%	169.84%	300.78%	-818.43%	-101.69%	-44.54%
Return on Assets (ROA)	1.30%	-11.77%	-28.17%	-48.30%	-52.15%	-43.72%
Return on Invested Capital (ROIC)	2.21%	-26.11%	-66.04%	-158.18%	-190.06%	-154.96%
Return on Capital Employed (ROCE)	-1.31%	-53.99%	-154.56%	-90.43%	-59.04%	-47.27%
FCF Yield	0.38%	0.48%	-	-	-	-
Buyback Yield / Dilution	-5.21%	-4.69%	-2.85%	-0.38%	-2.37%	-8.21%
Total Shareholder Return	-5.21%	-4.69%	-2.85%	-0.38%	-2.37%	-8.21%

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q